Loading...
Loading...
Sunesis Pharmaceuticals, Inc.
SNSS today announced the presentation of results from a Washington University-sponsored Phase 1 trial of vosaroxin plus azacitidine in patients with myelodysplastic syndrome, and from an analysis of the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in relapsed/refractory acute myeloid leukemia (AML) at the 57th American Society of Hematology Annual Meeting in Orlando, Florida. The posters, titled "A Phase I Study of Vosaroxin plus Azacitidine for Patients with Myelodysplastic Syndrome" (publication number 1686) and "Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo plus Cytarabine in the Phase 3 VALOR Study" (publication number 2560) are available at www.sunesis.com.
A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
In a Phase 1/2, open label, dose-escalation trial sponsored by the Washington University School of Medicine, patients with MDS who may have received up to three prior cycles of hypomethylating agent-based therapy were given vosaroxin and azacitidine for a maximum of six cycles. The Phase 1 portion of the study was designed to determine the maximum tolerated dose and dose limiting toxicity of the
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in